Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.

摘要: Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in catabolism of 5-fluorouracil, one most widely used cancer chemotherapeutic agents. Previous studies have demonstrated clinical importance determination DPD patients, suggesting that efficacy and toxicity 5-fluorouracil may directly relate to activity both tumor host tissues. In present study, was determined 50 pairs uninvolved liver specimens Chinese patients with hepatocellular carcinoma. Mean tissues (0.45 +/- 0.02 nmol/min/mg protein) significantly higher than (0.34 0.03 protein). Statistical analysis revealed no significant differences among different age gender groups. Compared previously reported studies, hepatomas were found relatively high activity. Since levels would be expected metabolize these findings provide an explanation for relative resistance hepatoma implications designing a new therapeutic strategy such as modulation chemotherapy by inhibitors.